Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 4/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | NNMT | P40261 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14570422 | 0.82 | OPRK1 (0.70) | OPRK1KCNH2OPRM1OPRD1 | |
| SCHEMBL12367586 | 0.81 | NAMPT (0.54) | OPRK1NAMPT | |
| SCHEMBL5531111 | 0.80 | ALDH1A1 (0.58) | OPRK1KCNH2 | |
| SCHEMBL14570425 | 0.79 | OPRK1 (0.59) | OPRK1KCNH2HTR2AOPRM1OPRD1 | |
| SCHEMBL12367604 | 0.79 | OPRK1 (0.42) | OPRK1KCNH2SIGMAR1HRH1CCR3 | |
| SCHEMBL12367663 | 0.79 | OPRK1 (0.42) | OPRK1KCNH2HRH3NAMPT | |
| SCHEMBL5519275 | 0.77 | OPRK1 (0.53) | OPRK1KCNH2NNMTHRH3OPRM1 | |
| SCHEMBL14597172 | 0.77 | OPRK1 (0.53) | OPRK1KCNH2NNMTHRH3OPRM1 | |
| SCHEMBL5523023 | 0.76 | OPRK1 (0.51) | OPRK1KCNH2OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL5525297 | 0.76 | OPRK1 (0.52) | OPRK1KCNH2NNMTHRH3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697307-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2014-03-12 | — | — | EP | claimed |
| US-7196100-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-03-27 | — | — | US | claimed |
| US-20070010558-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-01-11 | — | — | US | claimed |
| EP-1697307-A1 | OPIOID RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2006-09-06 | — | — | EP | claimed |
| WO-2005061442-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-07-07 | — | — | WO | claimed |
| EP-1697307-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-1697307-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20110207734-A1 | Azine Derivatives and Methods of Use Thereof | PALANI ANANDAN | 2011-08-25 | — | — | US | disclosed |
| US-20110207734-A1 | Azine Derivatives and Methods of Use Thereof | PALANI ANANDAN | 2011-08-25 | — | — | US | disclosed |
| US-7196100-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196100-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196100-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070010558-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-01-11 | — | — | US | disclosed |
| US-20070010558-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-01-11 | — | — | US | disclosed |
| US-20070010558-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-01-11 | — | — | US | disclosed |
| EP-1697307-A1 | OPIOID RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005061442-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207734-A1 | Azine Derivatives and Methods of Use Thereof | AZI2, GPR119, GID4 | OPRK1 252/4885KCNH2 414/4885NNMT 906/4885 |
| US-20070010558-A1 | Opioid receptor antagonists | OPRM1, OPRK1, OPRL1 | OPRK1 2/4885KCNH2 543/4885NNMT 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.